<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33547">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017119</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-282-10/11-1</org_study_id>
    <nct_id>NCT02017119</nct_id>
  </id_info>
  <brief_title>Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients</brief_title>
  <official_title>Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients: Impact on the Recurrence of Encephalopathy, Tolerance and Adherence to Treatment, Costs, and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <authority>Mexico: Secretaria de Salud</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy (HE) is an important complication of liver cirrhosis. Lactulose is a
      first line treatment for HE, but the adherence to this treatment is relatively low, due to
      side effects such as diarrhea, distention, etc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lactulose is a first line treatment for HE, but the adherence to this treatment is
      relatively low due to side effects. Lactulose-paraffin recently available in the market can
      be used for the treatment of HE, and possibly have fewer side effects.

      The aim of this study was to compare the adherence of the treatment of lactulose and
      lactulose-paraffin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adherence to treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Provide evidence of better adherence to treatment with lactulose-paraffin in cirrhotic patients with a history of hepatic encephalopathy, which should be reflected in fewer hospitalizations, lower costs and better quality life.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose-paraffin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparison between Lactulose and Lactulose-Paraffin</intervention_name>
    <arm_group_label>Lactulose</arm_group_label>
    <arm_group_label>Lactulose-paraffin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis

          -  History of an event of hepatic encephalopathy.

          -  Ambulatory patients

        Exclusion Criteria:

          -  Alcoholism with active ingest of alcohol in the last 6 months

          -  Labour turn-overs

          -  Pregnancy

          -  Personal history of surgery in the last 4 weeks

          -  Spontaneous bacterial Peritonitis

          -  Use of neuropsychiatric drugs

          -  Neuropsychiatric disorders (Schizophrenia, bipolar disorder, major depression,
             dementia and Attention-deficit hyperactivity disorder)

          -  Thyroid disorders without replacement therapy

          -  Renal failure

          -  Hepatic or renal transplant

          -  Personal history of hepatocellular carcinoma

          -  Placement of transjugular intrahepatic portosystemic shunt

          -  Use of a probiotic in the last 6 month
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
    <phone>54870900</phone>
    <phone_ext>2711</phone_ext>
    <email>detoal@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
      <phone>54870900</phone>
      <phone_ext>2711</phone_ext>
      <email>detoal@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aldo Torre Delgadillo, M.D. M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>Principal Investigator.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
